Fabrikstrasse 2, 4056 Basel
Location: Basel
Discipline: Pharmacology

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.


Pharmacology - Health - Jul 19
Chinese National Medical Products Administration (NMPA) approved Gilenya for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older.   Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China.
Pharmacology - Business - Jul 18

Continuing operations net sales up 8% (cc , +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +81% (cc) with increased initiation in hospital and ambulatory settings Oncology sales grew 9% (cc) driven by gr

Pharmacology - Health - Jul 11

After review of clinical data from the Generation Program studies, the sponsors concluded that the potential benefit for participants taking CNP520 no longer outweighs the risk Basel, July 11, 2019 - Novartis, Amgen and Banner Alzheimer's Institute today announced the decision to discontinue inve

Pharmacology - Health - Jul 2

Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary progressive MS (SPMS) patients, supporting the use of blood NfL levels as a biomarker -   EXPAND da

Pharmacology - Health - Jul 1

Data from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures -   STRIVE data show that 55% of patients on Aimovig 140 mg experienced at least a 50% reduction in the number

Health - Pharmacology - Jul 16

FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from standard ten months -   Vaso-occlusive crises (also called sickle cell pain crises) are unpredictable a

Health - Pharmacology - Jul 2

Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK More than 300,000 European men and women are diagnosed with lung cancer annually, making it the fourth most common cancer With launch Sandoz builds on

Pharmacology - Health - Jul 1

Basel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.

Pharmacology - Health - Jul 1

Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive treatment failures -   At week 24, patients on Aimovig experienced a sustained reduction in physical impair

website preview


Medicine and Life Sciences